


Reducing Anastomotic Leaks




In a meta-analysis of over 2,300 major elective surgery patients, those given IMPACT® formula were found to have a 44% lower risk of anastomotic leaks vs. control.⁸

Study Objective: To examine the relationship between pre-, peri- and postoperative use of IMPACT® immunonutrition (IM) formula and post-operative morbidity in 17 randomized clinical trials (n=2305) of major elective surgery.

Synopsis:

- Of 17 studies meta-analyzed, 14 were in GI cancer surgery, 2 in cardiac surgery and 1 in head and neck surgery. Control groups were given either standard formula, IV nutrition, or no nutrition support.
- In aggregate, studies demonstrated:
 - IM was associated with a 51% reduction in risk of postoperative infectious complications (RR=0.49; 95% CI, 0.42–0.58; p<0.0001).
 - A significant reduction in risk of anastomotic leak (44%, p=0.004), pneumonia, wound infections, abdominal abscesses and UTIs was shown in IM vs. control.
 - An intention to treat analysis also found significance for reduction in the risk of complications except for UTI.
- The pooled difference between the group means showed an average decrease of 3.1 days in length of stay (LOS) for patients receiving IM (p<0.05).
- All administration methods showed significant reduction in complications and LOS, with the order being preoperative> perioperative> postoperative.
- Authors concluded 0.5–1.0 L/day of IM containing arginine, omega-3 fatty acids and nucleotides (IMPACT® formula) for 5–7 days before major elective surgery is part of a proactive approach to infection control.

Post-Operative Anastomotic Leak



Studies with IMPACT® formula show a 44% reduction in risk of anastomotic leak (RR=0.56; 95% CI, 0.37–0.83; p=0.004)

Plot content based on values reported in Tables 4 and 5, Waitzberg et al., World J Surg 2006

IMPROVING SURGICAL OUTCOMES WITH

IMPACT® Immunonutrition Formulas

Contains a unique blend of arginine, omega-3 fatty acids (EPA+DHA from fish oil), and nucleotides shown to reduce complications in major elective surgery patients³⁻¹¹

Consistent outcomes in over **80 publications** in major elective surgeries, including:
Upper GI, Lower GI, Cardiac, Head and Neck, Bladder Cancer, Gyn-Oncology, Hip



Nutrition Information

| Serving Size | IMPACT ADVANCED RECOVERY® Drink | | IMPACT® Formula | IMPACT® Peptide 1.5 Formula |
|-----------------------------|---------------------------------|------------------------|------------------------|-----------------------------|
| | Per 178 mL carton | Per 534 mL (3 cartons) | Per 1000 mL | Per 1000 mL |
| Supplemental L-arginine (g) | 4.2 | 12.6 | 12.5 | 18.7 |
| EPA + DHA (g) | 1.1 | 3.3 | 1.7 | 4.9 |
| Nucleotides (g) | 0.43 | 1.3 | 1.2 | 1.8 |
| Calories (kcal) | 200 | 600 | 1,000 | 1,500 |
| Protein (g) | 18 (35% of total kcal) | 54 (35% of total kcal) | 56 (22% of total kcal) | 94 (25% of total kcal) |

Ordering Information

| PRODUCT | PRODUCT CODE | NDC FORMAT NUMBER | CASE UPC (GTIN) | PACKAGING |
|--------------------------------------|--------------|-------------------|-----------------|------------------------|
| IMPACT® Unflavored | 35810000 | 43900-0358-10 | 10043900358106 | 24-250 mL cartons/case |
| IMPACT® UltraPak® System | 35810800 | 43900-0358-18 | 10043900358182 | 6-1000 mL bags/case |
| IMPACT ADVANCED RECOVERY® Vanilla | 4390099291 | 43900-0992-90 | 00043900992914 | 15-178 mL cartons/case |
| IMPACT® Peptide 1.5 Unflavored | 4390097400 | 43900-0973-99 | 10043900974009 | 24-250 mL cartons/case |
| IMPACT® Peptide 1.5 UltraPak® System | 4390097371 | 43900-0973-70 | 10043900973712 | 6-1000 mL bags/case |

NDC Formatted Numbers are not actual National Drug Codes (NDC). They are product codes adjusted according to standard industry practice to meet the format requirements of certain suppliers and payers. Nestlé HealthCare Nutrition submits product information including various product codes to the compendia including First Data Bank, RedBook and Medispan but cannot confirm that the NDC Formatted Numbers submitted have been published by the compendia.

References 1. Mauskopf JA et al. *WJSO* 2012;10:136. 2. Braga M et al. *Nutrition* 2005;21:1078-1086. 3. Braga M et al. *Surgery* 2002;132(5):805-814. 4. Braga M et al. *Arch Surg* 2002;137:174-180. 5. Drover JW et al. *J Am Coll Surg* 2011;212(3):385-399. 6. Ferreras N et al. *Clin Nutr* 2005;24:55-65. 7. Rowan NR et al. *Oral Onc* 2016;54:42-46. 8. Waitzberg DL et al. *World J Surg* 2006;30:1592-1604. 9. Chapman JS et al. *Gynecologic Oncology* 2015;137:523-528. 10. Tepaske R et al. *JPEN* 2007;31(3):173-180. 11. Bertrand J et al. *World J Urol* 2014;32:233-237.

USE UNDER MEDICAL SUPERVISION. NOT INDICATED WHEN IMMUNE SUPPRESSION IS DESIRED.

www.NestleHealthScience.us • 1-800-422-ASK2 (2752)

All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland.
©2016 Nestlé. All rights reserved.

IPCT-12019-0616

